What is the mechanism of action of CJC-1295 + Ipamorelin Blend?

CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. For sourcing and quality-control applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The sourcing / quality / procurement interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What class of compound is CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend is classified as a GHRH + GHRP combination. Within this class, alternative names and analogues include CJC/Ipa, GH-Releasing Stack. The class-level pharmacology shapes both the clinical applications and the safety profile; the sourcing / quality / procurement literature treats CJC-1295 + Ipamorelin Blend alongside its class peers when evaluating relative merits.

What are the procurement red flags for CJC-1295 + Ipamorelin Blend?

Six markers to evaluate when sourcing CJC-1295 + Ipamorelin Blend: lot-specific COAs available; HPLC purity ≥98% confirmed; mass spec confirming Variable; endotoxin testing for SubQ-route material; physical address and regulatory disclosure on vendor site; cold-chain shipping options. Multiple missing markers = walk away. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How long until I see results from CJC-1295 + Ipamorelin Blend?

Acute effects from CJC-1295 + Ipamorelin Blend appear within the first week for downstream physiological adaptation. sourcing and quality-control endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend

Sourcing Guide

Sourcing CJC-1295 + Ipamorelin Blend from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. The canonical GHRH + GHRP stack — synergistic GH release with minimal off-target effects on cortisol or prolactin. The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.

Sourcing / Quality / Procurement Applications

Mass Spectrometry VerificationStorage ProtocolHPLC PurityRegulatory SourcingPricing Analysis

Key Takeaways

Procurement lens: CJC-1295 + Ipamorelin Blend sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching Variable.
Mechanism: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

For procurement of CJC-1295 + Ipamorelin Blend, the relevant QC framework covers analytical purity (HPLC), structural identity (mass spec), microbiological safety (endotoxin), and stoichiometric correctness where applicable. CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. The two pathways converge on the same somatotroph but use independent receptors, producing a multiplicative rather than additive GH pulse. Ipamorelin's selectivity avoids the cortisol/prolactin elevation seen with GHRP-6 and GHRP-2. The subsections below address each QC layer and the vendor-tier landscape.

HPLC purity and analytical identity

Minimum acceptable HPLC purity for CJC-1295 + Ipamorelin Blend is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of Variable (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.

Reconstitution and storage protocols

CJC-1295 + Ipamorelin Blend is typically supplied lyophilised in glass vials for reconstitution with bacteriostatic water. Standard reconstitution: dissolve at 1–2 mg/mL, store reconstituted material at 4°C, and use within 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Lyophilised storage at −20°C extends shelf life to 18–24 months for most peptides in this class.

COA evaluation and red flags

Acceptable CJC-1295 + Ipamorelin Blend certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

Sourcing / Quality / Procurement Applications

Red Flag Detection

For users targeting red flag detection, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Vial Inspection

Sourcing CJC-1295 + Ipamorelin Blend for vial inspection use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

COA Review

Pharmaceutical-grade compounded CJC-1295 + Ipamorelin Blend is the lowest-risk sourcing path for coa review use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

Cold Chain

For users targeting cold chain, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	100 mcg CJC + 200 mcg ipamorelin	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	60 mcg CJC + 200 mcg ipamorelin	4–6 weeks initial cycle
Sourcing Guide focus	SubQ	100 mcg CJC + 200 mcg ipamorelin	1-3x daily SubQ
Maintenance phase	SubQ	70 mcg CJC + 200 mcg ipamorelin	Ongoing with periodic pauses

Dose timing for CJC-1295 + Ipamorelin Blend is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses. Fasted dosing produces stronger GH pulses; meal-paired dosing blunts the response.

Stacking

CJC-1295 + Ipamorelin Blend stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

CJC-1295 + Ipamorelin Blend + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in sourcing / quality / procurement protocols.
CJC-1295 + Ipamorelin Blend + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in sourcing / quality / procurement protocols.
CJC-1295 + Ipamorelin Blend + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in sourcing / quality / procurement protocols.
CJC-1295 + Ipamorelin Blend + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with CJC-1295 + Ipamorelin Blend's mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Both components banned (S2) FDA: Unapproved Research: Off-label clinical use; mechanistic studies

Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible.

Lens-specific safety considerations for sourcing / quality / procurement use of CJC-1295 + Ipamorelin Blend: Lowest-side-effect profile of GH-releasing stacks. Site reactions and mild flushing possible. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Ipamorelin selective GH secretagogue

PMID 9849822

CJC-1295 + Ipamorelin Blend vs Related Peptides

Compound	Profile	Onset	Best For
CJC-1295 + Ipamorelin Blend	GHRH + GHRP combination	Mixed	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Visual quality inspection?

Lyophilised CJC-1295 + Ipamorelin Blend should be a uniform white powder adherent to the vial wall or as a freeze-dried cake. Discoloration, residue on the rubber septum, or particulate matter in the lyophilised product are reasons to request replacement before reconstituting.

Storage protocol?

Lyophilised: −20°C for 18–24 months. Reconstituted with bacteriostatic water: 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Cold-chain shipping is preferred for purchases; insulated packaging without active cooling is acceptable for shorter transit windows.

Lot variability across orders?

Even reputable vendors show some lot-to-lot variability. The QC-disciplined practice is to spot-check a fresh COA against the prior lot when re-ordering, and to track perceived response across lots. Substantial drift in subjective effects on a stable dose with a stable protocol often traces back to material quality rather than physiology.

What should I check on a CJC-1295 + Ipamorelin Blend COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching Variable Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

What route should I use for CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What is the evidence base for CJC-1295 + Ipamorelin Blend?

CJC-1295 + Ipamorelin Blend's evidence base sits at off-label clinical use; mechanistic studies. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Clinical Protocol

Start a CJC-1295 + Ipamorelin Blend Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified CJC-1295 + Ipamorelin Blend and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: Variable
Half-life: Mixed
WADA: Both components banned (S2)
FDA: Unapproved
Research: Off-label clinical use; mechanistic studies

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for CJC-1295 + Ipamorelin Blend unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for CJC-1295 + Ipamorelin Blend

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised